Progyny Financial Statements
NASDAQ: PGNYHealth CareMisc Health and Biotechnology ServicesUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
After hours: 27.93 0.00%
Progyny revenue and earnings
In fiscal 2025, Progyny generated $1.29 billion in revenue, up 10.4% from fiscal 2024, its 8th consecutive year of revenue growth. Net income was $58.5 million (+7.7% year over year), for a net margin of 4.5% versus a median of 5.7% in the prior 5 years. Gross margin was 23.6% (up from 21.7%) and operating margin 6.6%.
Diluted earnings per share came in at $0.65, up from $0.57. Over the last 5 fiscal years, PGNY's revenue has grown at a 30.2% compound annual rate.
Summary generated from market data by MetaCap's automated system. Methodology
Progyny income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.29B | 1.17B | 1.09B | 786.91M | 500.62M | 344.86M | 229.68M | 105.40M | 48.58M |
| Revenue growth (YoY) | +10.40% | +7.22% | +38.34% | +57.19% | +45.17% | +50.15% | +117.92% | +116.94% | — |
| Cost of Revenue | 984.18M | 913.86M | 849.80M | 619.59M | 388.49M | 274.80M | 184.18M | 85.97M | 41.18M |
| Gross Profit | 304.48M | 253.36M | 238.80M | 167.32M | 112.14M | 70.06M | 45.51M | 19.43M | 7.40M |
| Operating Expenses | 219.21M | 185.91M | 176.62M | 143.98M | 79.80M | 61.71M | 35.83M | 22.89M | 18.41M |
| Research & Development | 9.50M | — | — | — | — | — | — | — | — |
| Selling, General & Admin | 219.21M | 185.91M | 176.62M | 143.98M | 79.80M | 61.71M | 35.83M | 22.89M | 18.41M |
| Operating Income | 85.28M | 67.45M | 62.18M | 23.34M | 32.34M | 8.35M | 9.68M | -3.45M | -11.01M |
| Other Income (Expense) | 10.15M | 15.75M | 8.51M | 1.10M | 95.00K | 331.00K | -18.23M | -3.44M | -1.45M |
| Pretax Income | 95.43M | 83.20M | 70.69M | 24.44M | 32.44M | 8.68M | -8.56M | -6.89M | -12.46M |
| Income Tax | 36.91M | 28.87M | 8.65M | -5.92M | -33.33M | -37.78M | 12.00K | -1.78M | -3.00K |
| Net Income | 58.52M | 54.34M | 62.04M | 30.36M | 65.77M | 46.46M | -8.57M | 661.00K | -12.45M |
| Net Income growth (YoY) | +7.70% | -12.41% | +104.35% | -53.84% | +41.56% | — | -1396.37% | — | — |
| EPS (Basic) | 0.68 | 0.59 | 0.65 | 0.33 | 0.74 | 0.54 | -0.41 | 0.04 | -2.37 |
| EPS (Diluted) | 0.65 | 0.57 | 0.62 | 0.30 | 0.66 | 0.47 | -0.41 | 0.04 | -2.37 |
| Shares Outstanding (Basic) | 85.65M | 91.48M | 95.02M | 92.20M | 89.11M | 85.72M | 20.74M | 5.54M | 5.68M |
| Shares Outstanding (Diluted) | 89.86M | 95.45M | 100.67M | 99.96M | 100.36M | 99.06M | 20.74M | 5.54M | 5.68M |
| EBITDA | 90.22M | 70.63M | 64.47M | 24.94M | 33.64M | 10.25M | 11.81M | -1.57M | -9.45M |
| Gross Margin | 23.63% | 21.71% | 21.94% | 21.26% | 22.40% | 20.32% | 19.81% | 18.44% | 15.23% |
| Operating Margin | 6.62% | 5.78% | 5.71% | 2.97% | 6.46% | 2.42% | 4.21% | -3.28% | -22.65% |
| Net Margin | 4.54% | 4.66% | 5.70% | 3.86% | 13.14% | 13.47% | -3.73% | 63.00% | -25.63% |
This table shows 9 annual periods of Progyny's income statement, from FY 2025 back to FY 2017, across 19 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow PGNY's reporting calendar. What is a income statement?